HIV Genotyping Drug Resistance Assays Should Be Downclassified - Panel
This article was originally published in The Gray Sheet
Executive Summary
Downclassification of HIV genotyping drug resistance assays with special controls would serve the public health interest and "be of use to every AIDS patient in the lifetime of their illness," FDA staffers asserted Sept. 17 before the Blood Products Advisory Committee.